- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03297957
Fluorescence Imaging in Head and Neck Cancer
Evaluation of Fluorescence Imaging in Head and Neck Cancer
Fluorescent technology continues to advance in the detection of sentinel lymph nodes (SLNs). Currently, this requires switching from near-infrared light to white light to be able to identify the fluorescent tissue contrasting with normal surrounding tissue. Currently, no system has been studied specifically for head and neck sentinel lymph node biopsies using a hands free goggle system that can visualize white light (normal surgical visualization) and nearinfrared light (ICG fluorescence) simultaneously. This technology may have implications on the safety and accuracy of sentinel lymph node biopsy for head and neck mucosal and cutaneous tumors. Secondarily, this may reduce operative costs by decreasing the amount of time required to perform the SLNB procedure.
Regarding parathyroid identification, this technology has the potential to identify these very small glands during procedures they are at risk. These glands are not only at risk of inadvertent removal if not adequately identified, but may also be at risk if devascularized by manipulation during the surgical procedure. Therefore, early and accurate identification may decrease the rate of temporary and permanent hypoparathyroidism and hypocalcemia. This is not only an issue during thyroid and parathyroid surgery, but during laryngectomy surgery where the anatomic region these glands are located are often resected to remove at risk lymph nodes from cancer spread. Therefore, identifying these glands may help preserve parathyroid function in this patient population as well.
Study Overview
Status
Conditions
Intervention / Treatment
Study Type
Enrollment (Actual)
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
Missouri
-
Saint Louis, Missouri, United States, 63110
- Washington University School of Medicine
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Adults aged 18 years or older will be considered eligible.
Patients with head and neck malignancies, such as melanoma, non-melanoma cutaneous malignancies, or oral cavity squamous cell carcinoma. Patients with central neck pathology including thyroid neoplasms, parathyroid neoplasms, and laryngeal neoplasms undergoing surgical resection.
- Candidates for sentinel lymph node biopsy or central neck surgery
- Newly diagnosed with clinically node negative head and neck cancer being staged with sentinel lymph node biopsy.
- Not pregnant or breast feeding.
- Able to understand and willing to sign an IRB-approved written informed consent document.
- Able to understand written or spoken English.
Exclusion Criteria:
- History of allergy to iodide drugs or shellfish (iodine allergy)
- Pregnant or breast feeding
- Do not fit age criteria
- Prisoners
- Unable to provide written consent
Contraindications for surgery
*Presence of uncontrolled intercurrent illness including, but not limited to, ongoing or active infection of the head and neck, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements
- Receiving any other investigational agents
Study Plan
How is the study designed?
Design Details
- Primary Purpose: DIAGNOSTIC
- Allocation: NA
- Interventional Model: SINGLE_GROUP
- Masking: NONE
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
EXPERIMENTAL: Arm 1: Goggle Imaging
-Patient will then be taken to the operating room for this surgical procedure.
Prior to starting the operation, the patient will undergo injection of ICG around the tumor per standard techniques while in the operating room.
Those undergoing intraoperative visualization of parathyroid glands will not have any administration of ICG as these glands autofluoresce.
Patients will then undergo the standard SLN biopsy procedure (those undergoing parathyroid visualization will not undergo this).
The surgeon will put on the goggle system to attempt to identify the SLN using fluorescence guidance or parathryroid visualization.
After this is performed, the goggle system will be removed and the procedure will be completed per normal.
|
-Manufactured at Washington University
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Feasibility of using a novel fluorescence imaging device to detect a SLN as measured by the ability of the imaging device to identity the SLN by the surgeon during the standard biopsy procedure
Time Frame: Up to 1 week after surgery
|
-Feasibility will be assessed in terms of percentage of patients enrolled for whom peri-tumoral injection with ICG is performed successfully
|
Up to 1 week after surgery
|
Feasibility of using a novel fluorescence imaging device to detect a SLN as measured by the ability of the imaging device to identity the SLN by the surgeon during the standard biopsy procedure
Time Frame: Up to 1 week after surgery
|
-Feasibility will be assessed in terms of percentage patients whom the sentinel and superficial lymph nodes will be detected from the hands free goggle device
|
Up to 1 week after surgery
|
Feasibility of using a novel fluorescence imaging device to detect a SLN as measured by the ability of the imaging device to identity the SLN by the surgeon during the standard biopsy procedure
Time Frame: Up to 1 week after surgery
|
-Feasibility will be assessed in terms of percentage of total lesions identified from the new technique are truly positive as confirmed by biopsy
|
Up to 1 week after surgery
|
Feasibility of using a novel fluorescence imaging device to detect a SLN as measured by the ability of the imaging device to identity the SLN by the surgeon during the standard biopsy procedure
Time Frame: Up to 1 week after surgery
|
-Feasibility will be assessed in terms of the the percentage of total positive SNLs being missed from the new device
|
Up to 1 week after surgery
|
Ability of the hands-free goggle system to identify parathryoid glands during central neck surgeries
Time Frame: Up to 1 week after surgery
|
Up to 1 week after surgery
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Determine if there is contrast between SLN and surrounding tissues using the novel fluorescence imaging device
Time Frame: Up to 1 week after surgery
|
Up to 1 week after surgery
|
Collaborators and Investigators
Investigators
- Principal Investigator: Ryan S Jackson, M.D., Washington University School of Medicine
Publications and helpful links
Study record dates
Study Major Dates
Study Start (ACTUAL)
Primary Completion (ACTUAL)
Study Completion (ACTUAL)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (ACTUAL)
Study Record Updates
Last Update Posted (ACTUAL)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- 201708068
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Head and Neck Cancer
-
Robert FerrisAmgenCompletedHead and Neck Cancer | Cancer of Head and Neck | Head Cancer | Neck Cancer | Neoplasms, Head and Neck | Cancer of the Head and Neck | Cancer of Neck | Upper Aerodigestive Tract Neoplasms | Neck Neoplasms | Cancer of the Head | Cancer of the Neck | UADT Neoplasms | Cancer of Head | Head Neoplasms | Head, Neck Neoplasms | Neoplasms, Head and other conditionsUnited States
-
Assiut UniversityRecruitingHead and Neck Cancer | Head and Neck Neoplasms | Cancer of Head and Neck | Neoplasms, Head and Neck | Cancer of the Head and NeckEgypt
-
Mayo ClinicRecruitingCancer Head Neck | Cancer Neck | Cancer, HeadUnited States
-
IRCCS Policlinico S. MatteoNestlé Health Science Spain; Akern SrlCompletedHead-neck CancerItaly
-
University of California, San FranciscoCompleted
-
Chinook Therapeutics, Inc. (formerly Aduro)TerminatedRecurrent Head and Neck Cancer | Metastatic Head and Neck CancerUnited States
-
M.D. Anderson Cancer CenterNational Cancer Institute (NCI)TerminatedHead And Neck CancerUnited States
-
National Cancer Institute (NCI)TerminatedRecurrent Head and Neck Cancer | Metastatic Head and Neck CancerUnited States
-
Radboud University Medical CenterUnknown
-
Centre Oscar LambretUnknownEpidermoid Head and Neck CancerFrance
Clinical Trials on Hands-free goggle system
-
University of Alabama at BirminghamU.S. Department of EducationCompletedCerebral Hemiplegia
-
University of FloridaActive, not recruitingInsufficient LactationUnited States
-
Tarek AlsaiedActive, not recruitingSingle-ventricleUnited States
-
University of MiamiRecruitingLaryngeal Cancer | LaryngectomyUnited States
-
Washington University School of MedicineWithdrawnHepatobiliary Surgery
-
UnitedHealth GroupCompletedChildhood ObesityUnited States
-
Hôpital Léon BérardTerminated
-
St. Justine's HospitalCompletedPain | Procedural AnxietyCanada